NCT01296711View on ClinicalTrials.gov

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

PHASE2TerminatedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

March 7, 2011

Primary Completion Date

May 1, 2013

Study Completion Date

August 5, 2013

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

CDP6038 (olokizumab)

100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks

Trial Locations (55)

Unknown

166, Mesa

154, Phoenix

118, Scottsdale

103, Hot Springs

127, Covina

148, La Jolla

184, Long Beach

177, Los Angeles

104, Palo Alto

129, Santa Maria

164, Upland

141, Hamden

111, Lewes

151, DeBary

114, Jupiter

157, Tampa

183, Tampa

116, Idaho Falls

160, Moline

168, Springfield

133, Cedar Rapids

172, Kansas City

185, Saint Clair Shores

112, St Louis

134, St Louis

102, Lincoln

171, Freehold

152, Toms River

174, Brooklyn

170, Charlotte

150, Cincinnati

100, Dayton

110, Oklahoma City

165, Duncansville

105, Nashville

135, Austin

128, Dallas

126, Houston

132, Houston

138, Houston

181, Houston

145, Mesquite

143, Nassau Bay

122, San Antonio

144, Tomball

142, Victoria

139, Chesapeake

175, Tacoma

136, Beckley

167, Clarksburg

401, Brussels

400, Liège

206, Essex

208, Southampton

209, Torquay

Sponsors

Collaborators (1)

R-Pharm
All Listed Sponsors
collaborator

R-Pharm

INDUSTRY

lead

UCB BIOSCIENCES, Inc.

INDUSTRY

NCT01296711 - Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 | Biotech Hunter | Biotech Hunter